Carle W K, Wade A G, Kill D C, Poland M
Community Pharmacology Services, Clydebank, Scotland.
J Rheumatol Suppl. 1992 Nov;36:58-62.
In a double blind, randomized, parallel group study, 197 patients with osteoarthritis (OA) received nabumetone (1000 mg/day) or indomethacin (75 mg/day) for 6 weeks and doses could be doubled. Doubling the dose resulted in a 100 or 67% increase in pain relief with nabumetone or indomethacin, respectively. Significantly more patients experienced at least 1 severe adverse event with indomethacin than with nabumetone. With nabumetone, the incidence of adverse events did not increase with dose. However, with the increase in dose, the incidence of all adverse events and gastrointestinal events increased in indomethacin treated patients. Nabumetone was as effective as indomethacin for the treatment of OA. However, significantly fewer nabumetone treated patients experienced severe adverse events and the frequency of events did not increase with dose.
在一项双盲、随机、平行组研究中，197例骨关节炎（OA）患者接受萘丁美酮（1000毫克/天）或吲哚美辛（75毫克/天）治疗6周，剂量可加倍。剂量加倍后，萘丁美酮或吲哚美辛的疼痛缓解率分别提高了100%或67%。与萘丁美酮相比，使用吲哚美辛的患者发生至少1次严重不良事件的人数明显更多。使用萘丁美酮时，不良事件的发生率不会随剂量增加而升高。然而，随着剂量增加，接受吲哚美辛治疗的患者中所有不良事件和胃肠道事件的发生率均有所增加。萘丁美酮治疗OA的效果与吲哚美辛相当。然而，接受萘丁美酮治疗的患者发生严重不良事件的人数明显较少，且事件发生频率不会随剂量增加而升高。
